-
BG1Luc ER TA Agonist Protocol: Appendix C of ICCVAM BRD 369KB
https://ntp.niehs.nih.gov/iccvam/docs/endo_docs/erta-tmer/appxc/annexc/c3-appxc.pdf
... C-268 11.1.2 Raloxifene Working Stock Solution ......C-269 11.2.1 Raloxifene Dilutions ......
-
ICCVAM Recommended Protocol for the LUMI-CELL ER Antagonist Assay 1.4MB
https://ntp.niehs.nih.gov/iccvam/methods/endocrine/ivsdocs/lumiantag12mar09.pdf
.........22 70 11.1.2 Raloxifene Stock Solution ............23 72 11.2.1 Raloxifene Dilutions ......
-
BG1Luc ER TA Protocol Standardization Study Report (Annex C of... 2.9MB
https://ntp.niehs.nih.gov/iccvam/docs/endo_docs/erta-tmer/appxc/annexc/c0-prot-stand.pdf
... C-32 Table 5-2 Concentrations of Raloxifene Tested in Eight-Point Half-Log vs. Nine-Point ... C-36 Table 5-3 Concentrations of Raloxifene in Reference Standard ......
-
ICCVAM Test Method Evaluation Report on the BG1Luc ER TA Test... 17.5MB
https://ntp.niehs.nih.gov/iccvam/docs/endo_docs/erta-tmer/bg1lucer-ta-tmer-combined.pdf
... In the antagonist testing, mean reduction ranged from 8.0 to 9.9 fold, and raloxifene ... NEG NEG NEG (3/3) NEG (3/3) NEG (3/3) Raloxifene HCl 82640-04-8 POS POS POS (1/1) POS ...
-
NICEATM Validation Study Report on the MCF-7 Cell Proliferation... 1.8MB
https://ntp.niehs.nih.gov/iccvam/methods/endocrine/mcf7/mcf7-valstudyreport-19jun12-wcv2-draft.pdf
... Raloxifene HCL (Ral, CASRN 82640-04-8) is used as the anti-estrogenic reference standard ... Eight concentrations of the reference anti-estrogen, raloxifene HCl, are tested at 10-fold ...
-
Addendum to ICCVAM Evaluation of In Vitro Test Methods for Detecting... 2.9MB
https://ntp.niehs.nih.gov/iccvam/docs/endo_docs/edaddendfinal.pdf
... for ER TA antagonist test methods is raloxifene, a "Substance Considered but not 14 ... Althou raloxifene may act as an agonist in some in vitro systems, it is also class as a ...
-
Minutes: BSC; Nov. 2008 308KB
https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/archives/2008/november/minutes_final.pdf
... This latter finding prompted the development of raloxifene, which is also a preventative that does not cause cancer. He wondered if additional data on carcinogenicity might upgrade ...
-
RoC Background Document: Tamoxifen; Oct. 30-31, 1997 2.3MB
https://ntp.niehs.nih.gov/ntp/newhomeroc/other_background/tamoxifen2_2apps_508.pdf
... A clinical trial comparing the effectiveness ofTamoxifen with Raloxifene, which may have fewer side effects, is scheduled to begin later this year. Experimental animal studies ...
-
Submission of the CertiChem Cell Proliferation Test Method for... 3.1MB
https://ntp.niehs.nih.gov/iccvam/methods/endocrine/endodocs/submdoc.pdf
... Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273: 1222-1225. 76 13. SUPPORTING MATERIALS (APPENDICES) MCF-7 ...
-
TR-597: 2-Hydroxy-4-methoxybenzophenone (CASRN 131-57-7) Administered... 3.2MB
https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr597_508.pdf
... and vitamin D (calcitriol) signaling and potentially on estrogen signaling (raloxifene). ... BB Complex 0.00181 -2.381 Inhibited Raloxifene Chemical drug 0.0272 -2.433 Inhibited ...
-
CERHR Monograph: Soy Infant Formula 122.6MB
https://ntp.niehs.nih.gov/ntp/ohat/genistein-soy/soyformula/soymonograph2010_508.pdf
... J Steroid Biochem Mol Biol 102, 60-70. 320 Garcia-Perez, M. A., et al. (2006). Comparative effects of estradiol, raloxifene, and genistein on the uterus of ovariectomized mice. ...
